Skip to main content
Top
Published in: Clinical Rheumatology 9/2014

01-09-2014 | Review Article

Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review

Authors: Ilaria Serio, Laurent Arnaud, Alexis Mathian, Pierre Hausfater, Zahir Amoura

Published in: Clinical Rheumatology | Issue 9/2014

Login to get access

Abstract

Distinction between infection and febrile disease flare in patients with systemic lupus erythematosus (SLE) is fundamental but often difficult to make, because clinical presentation can be similar. A systematic review of all articles indexed in PubMed through October 2013 was performed, in order to examine the potential role of procalcitonin (PCT) for the discrimination between SLE flare and infection. Among the 12 papers identified, 5 articles reported on PCT levels in SLE patients without infection, 6 compared PCT levels between SLE patients with flare versus those with infection, and 1 analyzed PCT levels in active patients with and without bacterial infection. These data suggest the absence of correlation between PCT levels and SLE disease activity. Furthermore, PCT levels detected during disease flares are lower than those observed during bacterial infections. PCT can therefore be used accurately in the early differentiation between bacterial infection and flare in febrile SLE patients. Raised PCT levels ≥0.5 μg/L should strongly suggest bacterial infection in the context of SLE, keeping in mind the limited data available in case of hemophagocytic syndrome. Elevated PCT levels in SLE patients should always prompt a thorough search for sources of potential infection.
Literature
1.
go back to reference Assicot M, Gendrel D, Carsin H et al (1993) High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341:515–518PubMedCrossRef Assicot M, Gendrel D, Carsin H et al (1993) High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341:515–518PubMedCrossRef
2.
go back to reference Gendrel D, Raymond J, Coste J et al (1999) Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. Pediatr Infect Dis J 18:875–881PubMedCrossRef Gendrel D, Raymond J, Coste J et al (1999) Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. Pediatr Infect Dis J 18:875–881PubMedCrossRef
3.
go back to reference Bernatsky S, Boivin JF, Joseph L et al (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54:2550–2557PubMedCrossRef Bernatsky S, Boivin JF, Joseph L et al (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54:2550–2557PubMedCrossRef
4.
go back to reference Rigante D, Mazzoni MB, Esposito S (2013) The cryptic interplay between systemic lupus erythematosus and infections. Autoimmun Rev 13:96–102PubMedCrossRef Rigante D, Mazzoni MB, Esposito S (2013) The cryptic interplay between systemic lupus erythematosus and infections. Autoimmun Rev 13:96–102PubMedCrossRef
5.
go back to reference Quintero OL, Rojas-Villarraga A, Mantilla RD et al (2012) Autoimmune diseases in the intensive care unit. An update. Autoimmun Rev 12:380–395PubMedCrossRef Quintero OL, Rojas-Villarraga A, Mantilla RD et al (2012) Autoimmune diseases in the intensive care unit. An update. Autoimmun Rev 12:380–395PubMedCrossRef
6.
7.
go back to reference Sciascia S, Ceberio L, Garcia-Fernandez C et al (2012) Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers. Autoimmun Rev 12:157–163PubMedCrossRef Sciascia S, Ceberio L, Garcia-Fernandez C et al (2012) Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers. Autoimmun Rev 12:157–163PubMedCrossRef
8.
go back to reference Muller B, Peri G, Doni A et al (2002) High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol 72:643–649PubMed Muller B, Peri G, Doni A et al (2002) High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol 72:643–649PubMed
9.
go back to reference Simon L, Gauvin F, Amre DK et al (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39:206–217PubMedCrossRef Simon L, Gauvin F, Amre DK et al (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39:206–217PubMedCrossRef
10.
go back to reference Uzzan B, Cohen R, Nicolas P et al (2006) Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 34:1996–2003PubMed Uzzan B, Cohen R, Nicolas P et al (2006) Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 34:1996–2003PubMed
11.
go back to reference Eberhard OK, Haubitz M, Brunkhorst FM et al (1997) Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 40:1250–1256PubMedCrossRef Eberhard OK, Haubitz M, Brunkhorst FM et al (1997) Usefulness of procalcitonin for differentiation between activity of systemic autoimmune disease (systemic lupus erythematosus/systemic antineutrophil cytoplasmic antibody-associated vasculitis) and invasive bacterial infection. Arthritis Rheum 40:1250–1256PubMedCrossRef
12.
go back to reference Schwenger V, Sis J, Breitbart A et al (1998) CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection 26:274–276PubMedCrossRef Schwenger V, Sis J, Breitbart A et al (1998) CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection 26:274–276PubMedCrossRef
13.
go back to reference Quintana G, Medina YF, Rojas C et al (2008) The use of procalcitonin determinations in evaluation of systemic lupus erythematosus. J Clin Rheumatol 14:138–142PubMedCrossRef Quintana G, Medina YF, Rojas C et al (2008) The use of procalcitonin determinations in evaluation of systemic lupus erythematosus. J Clin Rheumatol 14:138–142PubMedCrossRef
14.
go back to reference Lanoix JP, Bourgeois AM, Schmidt J et al (2010) Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus. Lupus 20:125–130PubMedCrossRef Lanoix JP, Bourgeois AM, Schmidt J et al (2010) Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus. Lupus 20:125–130PubMedCrossRef
15.
go back to reference Bador KM, Intan S, Hussin S et al (2012) Serum procalcitonin has negative predictive value for bacterial infection in active systemic lupus erythematosus. Lupus 21:1172–1177PubMedCrossRef Bador KM, Intan S, Hussin S et al (2012) Serum procalcitonin has negative predictive value for bacterial infection in active systemic lupus erythematosus. Lupus 21:1172–1177PubMedCrossRef
16.
go back to reference Shin KC, Lee YJ, Kang SW et al (2001) Serum procalcitonin measurement for detection of intercurrent infection in febrile patients with SLE. Ann Rheum Dis 60:988–989PubMedCentralPubMedCrossRef Shin KC, Lee YJ, Kang SW et al (2001) Serum procalcitonin measurement for detection of intercurrent infection in febrile patients with SLE. Ann Rheum Dis 60:988–989PubMedCentralPubMedCrossRef
17.
go back to reference Scire CA, Cavagna L, Perotti C et al (2006) Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol 24:123–128PubMed Scire CA, Cavagna L, Perotti C et al (2006) Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol 24:123–128PubMed
18.
go back to reference Ho W-L, Lan J-L, Chen D-Y et al (2009) Procalcitonin may be a potential biomarker for distinguishing bacterial infection from disease activity in febrile patients with systemic lupus erythematosus. Formos J Rheumatol 23:52–58 Ho W-L, Lan J-L, Chen D-Y et al (2009) Procalcitonin may be a potential biomarker for distinguishing bacterial infection from disease activity in febrile patients with systemic lupus erythematosus. Formos J Rheumatol 23:52–58
19.
go back to reference Kim HA, Jeon JY, An JM et al (2012) C-reactive protein is a more sensitive and specific marker for diagnosing bacterial infections in systemic lupus erythematosus compared to S100A8/A9 and procalcitonin. J Rheumatol 39:728–734PubMedCrossRef Kim HA, Jeon JY, An JM et al (2012) C-reactive protein is a more sensitive and specific marker for diagnosing bacterial infections in systemic lupus erythematosus compared to S100A8/A9 and procalcitonin. J Rheumatol 39:728–734PubMedCrossRef
20.
go back to reference Pyo JY, Park JS, Park YB et al (2013) Delta neutrophil index as a marker for differential diagnosis between flare and infection in febrile systemic lupus erythematosus patients. Lupus 22:1102–1109PubMedCrossRef Pyo JY, Park JS, Park YB et al (2013) Delta neutrophil index as a marker for differential diagnosis between flare and infection in febrile systemic lupus erythematosus patients. Lupus 22:1102–1109PubMedCrossRef
21.
go back to reference Jinquan Y, Bingling X, Huang Y et al (2014) Serum procalcitonin and C-reactive protein for differentiating bacterial infection from disease activity in patients with systemic lupus erythematosus. Mod Rheumatol 24(3):457–463CrossRef Jinquan Y, Bingling X, Huang Y et al (2014) Serum procalcitonin and C-reactive protein for differentiating bacterial infection from disease activity in patients with systemic lupus erythematosus. Mod Rheumatol 24(3):457–463CrossRef
22.
go back to reference Parodi A, Davi S, Pringe AB et al (2009) Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum 60:3388–3399PubMedCrossRef Parodi A, Davi S, Pringe AB et al (2009) Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum 60:3388–3399PubMedCrossRef
23.
go back to reference Borchers AT, Leibushor N, Naguwa SM et al (2012) Lupus nephritis: a critical review. Autoimmun Rev 12:174–194PubMedCrossRef Borchers AT, Leibushor N, Naguwa SM et al (2012) Lupus nephritis: a critical review. Autoimmun Rev 12:174–194PubMedCrossRef
24.
go back to reference Hildebrand A, Komenda P, Miller L et al (2010) Peritonitis and exit site infections in First Nations patients on peritoneal dialysis. Clin J Am Soc Nephrol 5:1988–1995PubMedCentralPubMedCrossRef Hildebrand A, Komenda P, Miller L et al (2010) Peritonitis and exit site infections in First Nations patients on peritoneal dialysis. Clin J Am Soc Nephrol 5:1988–1995PubMedCentralPubMedCrossRef
25.
go back to reference James MT, Laupland KB, Tonelli M et al (2008) Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis. Arch Intern Med 168:2333–2339PubMedCrossRef James MT, Laupland KB, Tonelli M et al (2008) Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis. Arch Intern Med 168:2333–2339PubMedCrossRef
26.
go back to reference Meisner M, Lohs T, Huettemann E et al (2001) The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesiol 18:79–87PubMedCrossRef Meisner M, Lohs T, Huettemann E et al (2001) The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesiol 18:79–87PubMedCrossRef
27.
go back to reference Lu XL, Xiao ZH, Yang MY et al (2012) Diagnostic value of serum procalcitonin in patients with chronic renal insufficiency: a systematic review and meta-analysis. Nephrol Dial Transplant 28:122–129PubMedCrossRef Lu XL, Xiao ZH, Yang MY et al (2012) Diagnostic value of serum procalcitonin in patients with chronic renal insufficiency: a systematic review and meta-analysis. Nephrol Dial Transplant 28:122–129PubMedCrossRef
28.
go back to reference Dumea R, Siriopol D, Hogas S et al (2013) Procalcitonin: diagnostic value in systemic infections in chronic kidney disease or renal transplant patients. Int Urol Nephrol 46(2):461–468PubMedCrossRef Dumea R, Siriopol D, Hogas S et al (2013) Procalcitonin: diagnostic value in systemic infections in chronic kidney disease or renal transplant patients. Int Urol Nephrol 46(2):461–468PubMedCrossRef
29.
go back to reference Doria A, Canova M, Tonon M et al (2008) Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev 8:24–28PubMedCrossRef Doria A, Canova M, Tonon M et al (2008) Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev 8:24–28PubMedCrossRef
Metadata
Title
Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review
Authors
Ilaria Serio
Laurent Arnaud
Alexis Mathian
Pierre Hausfater
Zahir Amoura
Publication date
01-09-2014
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 9/2014
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-014-2738-4

Other articles of this Issue 9/2014

Clinical Rheumatology 9/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.